DOCSLIB.ORG

Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia antioxidants Review Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Valentina Novak 1, Boris Rogelj 1,2 and Vera Župunski 1,* 1 Chair of Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, SI-1000 Ljubljana, Slovenia; [email protected] (V.N.); [email protected] (B.R.) 2 Department of Biotechnology, Jozef Stefan Institute, SI-1000 Ljubljana, Slovenia * Correspondence: [email protected] Abstract: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are severe neu- rodegenerative disorders that belong to a common disease spectrum. The molecular and cellular aetiology of the spectrum is a highly complex encompassing dysfunction in many processes, includ- ing mitochondrial dysfunction and oxidative stress. There is a paucity of treatment options aside from therapies with subtle effects on the post diagnostic lifespan and symptom management. This presents great interest and necessity for the discovery and development of new compounds and therapies with beneficial effects on the disease. Polyphenols are secondary metabolites found in plant-based foods and are well known for their antioxidant activity. Recent research suggests that they also have a diverse array of neuroprotective functions that could lead to better treatments for neurodegenerative diseases. We present an overview of the effects of various polyphenols in cell line and animal models of ALS/FTD. Furthermore, possible mechanisms behind actions of the most researched compounds (resveratrol, curcumin and green tea catechins) are discussed. Citation: Novak, V.; Rogelj, B.; Keywords: ALS; FTD; polyphenols; neurodegeneration; resveratrol; curcumin; catechin; EGCG Župunski, V. Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Antioxidants 2021, 10, 1328. 1. Introduction https://doi.org/10.3390/antiox With the ageing population, the treatment and management of neurodegenerative 10081328 diseases is a major and increasing challenge for health care systems and societies around the Academic Editor: Stanley Omaye world [1]. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons, resulting in deterioration of motor function, and frontotemporal dementia Received: 12 July 2021 (FTD) is a neurodegenerative disorder characterised by changes in personality, behaviour, Accepted: 20 August 2021 and language. The development of both diseases is a progressive and ultimately fatal Published: 23 August 2021 multistep process with a complex genetic and molecular background. Despite extensive research efforts, only two treatment options with limited effects on survival and motor Publisher’s Note: MDPI stays neutral function are currently approved for ALS. The vast majority of compounds researched as with regard to jurisdictional claims in possible ALS therapies until today were found to be ineffective in clinical trials, highlighting published maps and institutional affil- the need for further research [2]. Currently, only symptomatic treatments with limited iations. effects are available for FTD [3]. Polyphenols are natural compounds whose neuroprotective effects have been demon- strated in various models of neurodegenerative diseases such as Alzheimer’s and Parkin- son’s disease. These compounds are being explored for possible dietary intervention and Copyright: © 2021 by the authors. supplementation as preventive measures against neurodegenerative diseases, and also as Licensee MDPI, Basel, Switzerland. possible candidates for therapies to slow disease progression and alleviate symptoms [4]. This article is an open access article Due to the lack of disease-changing treatments for ALS/FTD and the growing interest distributed under the terms and in natural compounds as therapeutic agents, this article reviews an intriguing topic of conditions of the Creative Commons potential use of polyphenols in the development of treatments for ALS/FTD symptoms. Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Antioxidants 2021, 10, 1328. https://doi.org/10.3390/antiox10081328 https://www.mdpi.com/journal/antioxidants Antioxidants 2021, 10, 1328 2 of 15 Antioxidants 2021, 10, 1328 2 of 15 1.1.1.1. Amyotrophic Amyotrophic LateralLateral Sclerosis and and Frontotemporal Frontotemporal Dementia Dementia ALSALS isis aa neurodegenerativeneurodegenerative disease disease characte characterisedrised by by progressive progressive loss loss of ofboth both upper upper andand lower lower motormotor neurons.neurons. Initial Initial signs signs of of the the disease disease may may include include weakness weakness of the of the limbs limbs (in(in spinal-onset spinal-onset ALS)ALS) or difficulties difficulties with with speech speech and and swallowing swallowing (in (in bulbar-onset bulbar-onset ALS) ALS) [5]. [5]. DiseaseDisease progressionprogression eventually leads leads to to paralysis paralysis and and death death from from respiratory respiratory failure, failure, on on averageaverage 24 24 to to 5050 monthsmonths afterafter onsetonset [[6–10].6–10]. The worldwide worldwide incidence incidence of of ALS ALS is is 1.75 1.75 with with a reporteda reported mean mean age age at diagnosisat diagnosis between between 51 51 and and 69 69 years years [11 [11,12].,12]. ALS ALS cases cases can can be be divided di- intovided the into familial the familial form of form the diseaseof the disease (fALS, (fAL 5–15%S, 5–15% of patients), of patients), where where there there is a clearis a clear family history,family history, and the and predominant the predominant sporadic sporadic form (sALS) form (sALS) [13]. Frontotemporal [13]. Frontotemporal dementia dementia (FTD) is a(FTD) type ofis dementiaa type of dementia primarily primarily associated associated with alterations with alterations in the frontal in the andfrontal temporal and tem- lobes. Symptomsporal lobes. manifest Symptoms as changes manifest in as behaviour, changes in personality, behaviour, language,personality, and language, motor skills and mo- [14,15]. Thetor incidenceskills [14,15]. ofFTD The isincidence 1.6 and theof FTD mean is age1.6 and of onset the mean is 65 yearsage of [onset16]. FTD is 65 can years be divided[16]. intoFTD one can behavioural be divided into (bvFTD) one behavioural and two language (bvFTD) variants and two (or language primary variants progressive (or primary aphasias (PPA))progressive [14]. Mean aphasias survival (PPA)) time [14]. for Mean most surviv formsal of time FTD for is approximatelymost forms of FTD 8 years is approxi- [17]. Up to mately 8 years [17]. Up to 40% of FTD patients have a family history of the disease [18,19]. 40% of FTD patients have a family history of the disease [18,19]. Clinical, genetic, pathological and biochemical data show that there is an overlap be- Clinical, genetic, pathological and biochemical data show that there is an overlap tween ALS and FTD. First observations that ALS and FTD might be connected were made between ALS and FTD. First observations that ALS and FTD might be connected were in the early 1990s [20,21]. Data show that about half of ALS patients have cognitive im- made in the early 1990s [20,21]. Data show that about half of ALS patients have cognitive pairment and 15% meet the criteria for FTD [22,23]. Similarly, about 30% of patients with impairment and 15% meet the criteria for FTD [22,23]. Similarly, about 30% of patients FTD develop signs of motor dysfunction and 10–15% have ALS [24,25]. The discovery of with FTD develop signs of motor dysfunction and 10–15% have ALS [24,25]. The discovery common genetic causes and biological mechanisms further confirmed that ALS and FTD ofare common closely geneticassociated causes (Figure and 1) biological [5,26]. mechanisms further confirmed that ALS and FTD are closely associated (Figure1)[5,26]. FigureFigure 1.1. Genes involved in in pathologies pathologies along along the the ALS-FTD ALS-FTD spectrum. spectrum. The The most most common common ge- genetic causesnetic causes of the of disease the disease are highlighted are highlighted in bold. in bold. ALSALS andand FTDFTD pathologies are are multistep multistep processe processess that that affect affect many many aspects aspects of cellular of cellular activity.activity. TheThe most prominent prominent pathological pathological hallmark hallmark of both of both ALS ALS and andFTD FTDare changes are changes in inprotein protein homeostasis, homeostasis, including including protein protein misfolding misfolding and aggreg and aggregation,ation, altered altered localisation, localisa- tion,and anddefects defects in autophagic in autophagic and proteasomal and proteasomal degradation. degradation. The combination The combination of these mech- of these mechanismsanisms leads leads to the to formation the formation of toxic of cyto toxicplasmic cytoplasmic inclusions inclusions in motor in neurons motor neurons and sur- and surroundingrounding cells. cells. Proteins Proteins that that predominantly predominantly form form these these structures structures are aretwo two RNA-binding RNA-binding proteins,proteins, TARTAR DNADNA bindingbinding protein (TDP-43, (TDP-43, protein protein product product of ofTARDBPTARDBP), and), and fused fused in in sarcomasarcoma (FUS),(FUS), microtubule-associatedmicrotubule-associated protein tau (gene(gene MAPTMAPT), andand superoxidesuperoxide dismu-dis- tasemutase 1 (SOD1) 1 (SOD1) [27, 28[27,28].]. The The correlation correlation
Load more

Recommended publications
  • New Hypothesis and Treatment of Amyotrophic Lateral Sclerosis: a Holistic Point of View of the Key Evidence
    Final degree project New hypothesis and treatment of Amyotrophic lateral sclerosis: a holistic point of view of the key evidence Main subject: Pharmacology Secondary subjects: Physiopathology and Biochemistry David Rubert Sánchez June 2018 A l’équipe de Neurodialitics, spécialement à Bernard Renaud This work is licenced under a Creative Commons license. 2 Table of contents Abbreviations ................................................................................................................................ 4 1. Abstract ..................................................................................................................................... 5 Resum ............................................................................................................................................ 5 2. Introduction ............................................................................................................................... 6 2.1. Natural history .................................................................................................................... 6 2.2 Epidemiology ...................................................................................................................... 8 2.3. Primary cause and primary mechanism.............................................................................. 8 2.3.1 Genetic basis ................................................................................................................ 8 2.3.2 Epigenetic involvement .............................................................................................
    [Show full text]
  • The Protective Effect of Edaravone on Memory Impairment Induced By
    Psychiatry Research 281 (2019) 112577 Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres The protective effect of edaravone on memory impairment induced by chronic sleep deprivation T ⁎ Karem H. Alzoubia, , Heba S. Al Mosabihb, Amjad F. Mahasnehb a Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan b Department of Applied Biology, Jordan University of Science and Technology, Irbid, Jordan ARTICLE INFO ABSTRACT Keywords: Sleep plays a critical role in body health maintenance, whereas sleep deprivation (SD) negatively affects cog- Edaravone nitive function. Cognitive defects mainly memory impairment resulting from sleep deprivation were related to Sleep deprivation an increase in the level of oxidative stress in the body, including the brain hippocampus region. Edaravone is a Memory potent free radical scavenger having antioxidant effect. In the current study, edaravone's ability to prevent SD Maze induced cognitive impairment was tested in rats. Animals were sleep deprived 8 h/day for 4 weeks. Oxidative stress Concurrently, edaravone was administrated intraperitoneally for four weeks. Animals performance during cognitive testing was evaluated to display if edaravone has a role in the prevention of sleep deprivation induced memory impairment. Additionally, the role of antioxidant biomarkers glutathione peroxidase (GPx), catalase, glutathione (GSH), oxidized glutathione (GSSG), GSH/GSSG in this effect was investigated. The results showed that SD impaired both short- and long- term memories, and chronic edaravone administration prevented such effect. Additionally, edaravone prevented decreases in hippocampal GPx, catalase, GSH/GSSG ratio and nor- malized increases in GSSG levels, which were impaired by SD model. In conclusion, current result showed a protective effect of edaravone administration against SD induction that could be related to edaravone's ability to normalizing mechanisms related to oxidative balance.
    [Show full text]
  • Restoration of Dioxin-Induced Damage to Fetal Steroidogenesis and Gonadotropin Formation by Maternal Co-Treatment with A-Lipoic Acid
    Restoration of Dioxin-Induced Damage to Fetal Steroidogenesis and Gonadotropin Formation by Maternal Co-Treatment with a-Lipoic Acid Takayuki Koga1, Takumi Ishida1,2, Tomoki Takeda1, Yuji Ishii1, Hiroshi Uchi3, Kiyomi Tsukimori4, Midori Yamamoto5, Masaru Himeno5, Masutaka Furue3,6, Hideyuki Yamada1* 1 Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, 2 Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan, 3 Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan, 4 Department of Obstetrics, Fukuoka Children’s Hospital, Fukuoka, Japan, 5 Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Japan, 6 Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Abstract 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), an endocrine disruptor, causes reproductive and developmental toxic effects in pups following maternal exposure in a number of animal models. Our previous studies have demonstrated that TCDD imprints sexual immaturity by suppressing the expression of fetal pituitary gonadotropins, the regulators of gonadal steroidogenesis. In the present study, we discovered that all TCDD-produced damage to fetal production of pituitary gonadotropins as well as testicular steroidogenesis can be repaired by co-treating pregnant rats with a-lipoic acid (LA), an obligate co-factor for intermediary metabolism including energy production. While LA also acts as an anti-oxidant, other anti-oxidants; i.e., ascorbic acid, butylated hydroxyanisole and edaravone, failed to exhibit any beneficial effects. Neither wasting syndrome nor CYP1A1 induction in the fetal brain caused through the activation of aryl hydrocarbon receptor (AhR) could be attenuated by LA. These lines of evidence suggest that oxidative stress makes only a minor contribution to the TCDD-induced disorder of fetal steroidogenesis, and LA has a restorative effect by targeting on mechanism(s) other than AhR activation.
    [Show full text]
  • How Is Edaravone Effective Against Acute Ischemic Stroke And
    Review HowJCBNJournal0912-00091880-5086theKyoto,jcbn17-6210.3164/jcbn.17-62Review Society Japanof Clinical isfor Free edaravone Biochemistry Radical Research and Nutrition Japan effective against acute ischemic stroke and amyotrophic lateral sclerosis? Kazutoshi Watanabe,1 Masahiko Tanaka,2 Satoshi Yuki,3 Manabu Hirai4 and Yorihiro Yamamoto2,* 1Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshidacho, Aobaku, Yokohama 2270033, Japan 2School of Bioscience and Biotechnology, Tokyo University of Technology, 14041 Katakuracho, Hachioji 1920982, Japan 3Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 1710 NihonbashiKoamicho, Chuoku, Tokyo 1038405, Japan 4Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 3210 Doshomachi, Chuoku, Osaka 5418505, Japan (Received?? 30 June, 2017; Accepted 11 July, 2017; Published online 11 November, 2017) CreativestrictedvidedEdaravoneCopyright2018This the isuse, originalanCommons is opendistribution,©a 2018lowmolecularweight workaccess JCBNAttribution is article andproperly reproduction distributed License, cited. antioxidant underwhichin any the drugpermitsmedium, terms targeting ofunre- pro- the suppress such oxidation. Since lipid peroxyl radicals play the main peroxyl radicals among many types of reactive oxygen species. role in the chain reaction, development of drugs to scavenge lipid Because of its amphiphilicity, it scavenges both lipid and water peroxyl radicals is considered a priority. soluble
    [Show full text]
  • Improving Clinical Trial Outcomes in Amyotrophic Lateral Sclerosis
    REVIEWS Improving clinical trial outcomes in amyotrophic lateral sclerosis Matthew C. Kiernan 1,2 ✉ , Steve Vucic3, Kevin Talbot 4, Christopher J. McDermott 5,6, Orla Hardiman7,8, Jeremy M. Shefner 9, Ammar Al-Chalabi 10, William Huynh 1,2, Merit Cudkowicz11,12, Paul Talman 13, Leonard H. Van den Berg14, Thanuja Dharmadasa 4, Paul Wicks 15, Claire Reilly 16 and Martin R. Turner 4 Abstract | Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s — a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches. Neurodegeneration and dementia pose a major public owing to a lack of proven biomarkers and clinical trial health challenge worldwide owing to their devastating outcome measures10.
    [Show full text]
  • The Clinical Trial Landscape in Amyotrophic Lateral Sclerosis—Past, Present, and Future
    Received: 16 September 2019 | Revised: 8 December 2019 | Accepted: 27 January 2020 DOI: 10.1002/med.21661 REVIEW ARTICLE The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future Heike J. Wobst1 | Korrie L. Mack2,3 | Dean G. Brown4 | Nicholas J. Brandon1 | James Shorter2 1Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts Abstract 2 Department of Biochemistry and Biophysics, Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen- Perelman School of Medicine, University of erative disease marked by progressive loss of muscle func- Pennsylvania, Philadelphia, Pennsylvania ‐ 3Merck & Co, Inc, Kenilworth, New Jersey tion. It is the most common adult onset form of motor 4Hit Discovery, Discovery Sciences, neuron disease, affecting about 16 000 people in the United BioPharmaceuticals R&D, AstraZeneca, Boston, States alone. The average survival is about 3 years. Only two Massachusetts interventional drugs, the antiglutamatergic small‐molecule Correspondence riluzole and the more recent antioxidant edaravone, have Heike J. Wobst, Jnana Therapeutics, Northern been approved for the treatment of ALS to date. Therapeutic Avenue, Boston, MA 02210. Email: [email protected] strategies under investigation in clinical trials cover a range of different modalities and targets, and more than 70 dif- James Shorter, Department of Biochemistry and Biophysics, Perelman School of Medicine, ferent drugs have been tested in the clinic to date. Here, we University of Pennsylvania, Philadelphia, PA summarize and classify interventional therapeutic strategies 19104. Email: [email protected] based on their molecular targets and phenotypic effects. We also discuss possible reasons for the failure of clinical trials in Present address Heike J. Wobst, Dean G.
    [Show full text]
  • The Effect of Edaravone on Amyotrophic Lateral Sclerosis
    Review J Neurol Res. 2020;10(5):150-159 The Effect of Edaravone on Amyotrophic Lateral Sclerosis Brandon Nightingale Abstract disorder can be caused by myriad gene mutations [2]. ALS is associated with ≥ 30 gene mutations, with evidence of oligo- Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, is genic inheritance and genetic pleiotropy [3]. This is different fatal within 3 years of symptom onset. Both upper motor neurons and from a homogeneous disorder in which the catalytic event for lower motor neurons are targeted. It is hypothesized that: edaravone is the disorder is the same for all patients. ALS is considered ei- effective at managing ALS. This review article used a combination of ther sporadic (SALS) or familial (FALS), in which 10% of the secondary and primary research articles to gain a plethora of informa- cases are inherited in a familial pattern [4]. tion to help test this hypothesis. Using PubMed, research articles were The characteristic feature for ALS is the involvement of studied to identify important information. For the Introduction, both both upper motor neurons (UMNs) and lower motor neurons secondary and primary articles were used without a limitation on pub- (LMNs), which present with defining features when a lesion lication date. For the Results section, only primary articles were used occurs in the respective neuron. When a lesion takes place in an which had to have been published no earlier than 2006. The Results LMN, the characteristic findings will be weakness, muscle at- section of this review helped to support the hypothesis that edaravone rophy and fasciculations. In contrast, when a lesion takes place is effective at managing ALS.
    [Show full text]
  • Protective Effects of Combined Treatment with Mild Hypothermia
    INTERNATIONAL JOURNAL OF ONCOLOGY 57: 500-508, 2020 Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation HANG YU1*, ZHIDIAN WU2*, XIAOZHI WANG2, CHANG GAO3, RUN LIU2, FUXIN KANG2 and MINGMING DAI4 1Department of Critical Care Medicine, Hainan Medical University; 2Department of Critical Care Medicine, The Second Affiliated Hospital of Hainan Medical University;3 Department of Pathophysiology, Hainan Medical University; 4Department of Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China Received November 5, 2019; Accepted April 27, 2020 DOI: 10.3892/ijo.2020.5077 Abstract. Mild hypothermia (MH) and edaravone (EDA) exerted synergistic neuroprotective effects against cerebral exert neuroprotective effects against cerebral ischemia/reper- I/R injury involving changes in the Nrf2/HO-1 pathway. fusion (I/R) injury through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. However, whether Introduction MH and EDA exert synergistic effects against cerebral I/R injury remains unknown. The aim of the present study was Stroke, which is characterized by loss of neurological function to investigate the effects and mechanism of action of MH in caused by ischemia of the brain, intracerebral hemorrhage combination with EDA in cerebral I/R injury. A rat cerebral or subarachnoid hemorrhage (1), is associated with high I/R injury model was constructed by middle cerebral artery morbidity and mortality rates (2,3). It has been demonstrated occlusion (MCAO) followed by reperfusion, and the mice were that, by inducing excitotoxicity, cerebral ischemia/reperfusion treated by MH, EDA or the inhibitor of the Nrf2 signaling (I/R) injury is a critical factor responsible for poor prognosis pathway brusatol (Bru).
    [Show full text]
  • The Phenolic Antioxidant 3,5-Dihydroxy-4-Methoxybenzyl
    Journal of Clinical Medicine Article The Phenolic Antioxidant 3,5-dihydroxy-4-methoxybenzyl Alcohol (DHMBA) Prevents Enterocyte Cell Death under Oxygen-Dissolving Cold Conditions through Polyphyletic Antioxidant Actions Moto Fukai 1,* , Takuya Nakayabu 1, Shintaro Ohtani 1, Kengo Shibata 1, Shingo Shimada 1 , Soudai Sakamoto 1 , Hirotoshi Fuda 2, Takayuki Furukawa 2, Mitsugu Watanabe 2,3, Shu-Ping Hui 2, Hitoshi Chiba 2,4, Tsuyoshi Shimamura 5 and Akinobu Taketomi 1 1 Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Nishi 7, Kita 15, Kita-ku, Sapporo 060-8638, Hokkaido, Japan; [email protected] (T.N.); [email protected] (S.O.); [email protected] (K.S.); [email protected] (S.S.); [email protected] (S.S.); [email protected] (A.T.) 2 Faculty of Health Sciences, Graduate School of Health Sciences, Hokkaido University, Nishi5, Kita12, Kita-ku, Sapporo 060-0812, Hokkaido, Japan; [email protected] (H.F.); [email protected] (T.F.); [email protected] (M.W.); [email protected] (S.-P.H.); [email protected] (H.C.) 3 Watanabe Oyster Laboratory Co. Ltd., 490-3, Shimoongata-cho, Hachioji 190-0154, Tokyo, Japan 4 Department of Nutrition, Sapporo University of Health Sciences, 1-15, 2 chome, Nakanumanishi4jou, Higashi-ku, Sapporo 007-0894, Hokkaido, Japan Citation: Fukai, M.; Nakayabu, T.; 5 Division of Organ Transplantation, Central Clinical Facilities, Hokkaido University Hospital, Nishi5 Kita14, Ohtani, S.; Shibata, K.; Shimada, S.; Kita-ku, Sapporo 060-8648, Hokkaido, Japan; [email protected] Sakamoto, S.; Fuda, H.; Furukawa, T.; * Correspondence: [email protected]; Tel.: +81-11-7065927; Fax: +81-11-7177515 Watanabe, M.; Hui, S.-P.; et al.
    [Show full text]
  • Dihydrolipoic Acid Protects Against
    Bian et al. Journal of Neuroinflammation (2020) 17:166 https://doi.org/10.1186/s12974-020-01836-y RESEARCH Open Access Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat Hetao Bian, Gaohua Wang*, Junjie Huang, Liang Liang, Yage Zheng, Yanyan Wei, Hui Wang, Ling Xiao and Huiling Wang Abstract Background: Recently, depression has been identified as a prevalent and severe mental disorder. However, the mechanisms underlying the depression risk remain elusive. The neuroinflammation and NLRP3 inflammasome activation are known to be involved in the pathology of depression. Dihydrolipoic acid (DHLA) has been reported as a strong antioxidant and exhibits anti-inflammatory properties in various diseases, albeit the direct relevance between DHLA and depression is yet unknown. The present study aimed to investigate the preventive effect and potential mechanism of DHLA in the lipopolysaccharide (LPS)-induced sickness behavior in rats. Methods: Adult male Sprague–Dawley rats were utilized. LPS and DHLA were injected intraperitoneally every 2 days and daily, respectively. Fluoxetine (Flu) was injected intraperitoneally daily. PD98059, an inhibitor of ERK, was injected intraperitoneally 1 h before DHLA injection daily. Small interfering ribonucleic acid (siRNA) for nuclear factor erythroid 2-like (Nrf2) was injected into the bilateral hippocampus 14 days before the DHLA injection. Depression-like behavior tests were performed. Western blot and immunofluorescence staining detected the ERK/ Nrf2/HO-1/ROS/NLRP3 pathway-related proteins. Results: The DHLA and fluoxetine treatment exerted preventive effects in LPS-induced sickness behavior rats. The DHLA treatment increased the expression of ERK, Nrf2, and HO-1 but decreased the ROS generation levels and reduced the expression of NLRP3, caspase-1, and IL-1β in LPS-induced sickness behavior rats.
    [Show full text]
  • Hydroxyurea Scavenges Free Radicals and Induces the Expression of Antioxidant Genes in Human Cell Cultures Treated with Hemin
    ORIGINAL RESEARCH published: 17 July 2020 doi: 10.3389/fimmu.2020.01488 Hydroxyurea Scavenges Free Radicals and Induces the Expression of Antioxidant Genes in Human Cell Cultures Treated With Hemin Sânzio Silva Santana 1,2, Thassila Nogueira Pitanga 1,2, Jeanne Machado de Santana 1, Dalila Lucíola Zanette 1, Jamile de Jesus Vieira 1, Sètondji Cocou Modeste Alexandre Yahouédéhou 1, Corynne Stéphanie Ahouefa Adanho 1, Sayonara de Melo Viana 1, Nivea Farias Luz 1, Valeria Matos Borges 1 and Marilda Souza Goncalves 1,3* 1 Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (IGM/FIOCRUZ-BA), Salvador, Brazil, 2 Faculdade de Biomedicina, Universidade Católica do Salvador (UCSal), Salvador, Brazil, 3 Faculdade de Farmácia, Universidade Federal da Bahia (UFBA), Salvador, Brazil Edited by: The excessive release of heme during hemolysis contributes to the severity of sickle Caroline Le Van Kim, cell anemia (SCA) by exacerbating hemoglobin S (HbS) autoxidation, inflammation and Université Paris Diderot, France systemic tissue damage. The present study investigated the effect of hydroxyurea Reviewed by: Nicola Conran, (HU) on free radical neutralization and its stimulation of antioxidant genes in human Campinas State University, Brazil peripheral blood mononuclear cells (PBMC) and human umbilical vein endothelial cells Marc Romana, INSERM U1134 Biologie Intégrée du (HUVEC) in the presence or absence of hemin. HU (100 and 200 µM) significantly Globule Rouge, France reduced the production of intracellular reactive oxygen species (ROS) induced by hemin *Correspondence: at 70 µM in HUVEC. HUVECs treated with HU+hemin presented significant increases Marilda Souza Goncalves in nitric oxide (NO) production in culture supernatants. HU alone or in combination mari@bahia.fiocruz.br with hemin promoted the induction of superoxide dismutase-1 (SOD1) and glutathione Specialty section: disulfide-reductase (GSR) in HUVECs and PBMCs, and glutathione peroxidase (GPX1) This article was submitted to in PBMCs.
    [Show full text]
  • The Neuroprotective Effect of Hesperidin in NMDA-Induced Retinal
    www.nature.com/scientificreports OPEN The neuroprotective efect of hesperidin in NMDA-induced retinal injury acts by suppressing oxidative Received: 19 January 2017 Accepted: 22 June 2017 stress and excessive calpain Published online: 31 July 2017 activation Shigeto Maekawa1, Kota Sato1,2, Kosuke Fujita3, Reiko Daigaku1, Hiroshi Tawarayama3, Namie Murayama1, Satoru Moritoh1, Takeshi Yabana1, Yukihiro Shiga1, Kazuko Omodaka1,2, Kazuichi Maruyama1, Koji M. Nishiguchi4 & Toru Nakazawa1,2,3,4 We found that hesperidin, a plant-derived biofavonoid, may be a candidate agent for neuroprotective treatment in the retina, after screening 41 materials for anti-oxidative properties in a primary retinal cell culture under oxidative stress. We found that the intravitreal injection of hesperidin in mice prevented reductions in markers of the retinal ganglion cells (RGCs) and RGC death after N-methyl- D-aspartate (NMDA)-induced excitotoxicity. Hesperidin treatment also reduced calpain activation, reactive oxygen species generation and TNF-α gene expression. Finally, hesperidin treatment improved electrophysiological function, measured with visual evoked potential, and visual function, measured with optomotry. Thus, we found that hesperidin suppressed a number of cytotoxic factors associated with NMDA-induced cell death signaling, such as oxidative stress, over-activation of calpain, and infammation, thereby protecting the RGCs in mice. Therefore, hesperidin may have potential as a therapeutic supplement for protecting the retina against the damage associated with excitotoxic injury, such as occurs in glaucoma and diabetic retinopathy. Oxidative stress is a major cause of various neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis1. In the retina, oxidative stress is believed to be an important risk factor for age-related macular degeneration, diabetic retinopathy (DR), and glaucoma.
    [Show full text]